Immunovant, Inc.

Equities

IMVT

US45258J1025

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
35.3 USD -0.20% Intraday chart for Immunovant, Inc. -4.59% -16.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target MT
Immunovant Posts Narrower Fiscal Q3 Loss MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Jobs Report Tops -2- DJ
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing MT
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM
Sector Update: Health Care Stocks Edge Higher Premarket Thursday MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating MT
Immunovant Gets Positive Data From Graves' Disease Treatment Trial DJ
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours MT
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates CI
Top Premarket Decliners MT
Deutsche Bank Initiates Coverage on Immunovant With Buy Rating, $50 Price Target MT
Immunovant Insider Sold Shares Worth $490,697, According to a Recent SEC Filing MT
Immunovant Insider Sold Shares Worth $504,567, According to a Recent SEC Filing MT
Immunovant Insider Sold Shares Worth $490,668, According to a Recent SEC Filing MT
UBS Raises Immunovant Price Target to $56 From $55, Maintains Buy Rating MT
Sector Update: Health Care Stocks Decline Premarket Tuesday MT
Roivant Sciences' Immunovant Reports 'Positive' Initial Data From Phase 1 Study of IMVT-1402 MT
Transcript : Immunovant, Inc. - Special Call
Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults CI
Truist Adjusts Price Target on Immunovant to $48 From $30, Maintains Buy Rating MT
Chart Immunovant, Inc.
More charts
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
35.3 USD
Average target price
50.73 USD
Spread / Average Target
+43.72%
Consensus
  1. Stock
  2. Equities
  3. Stock Immunovant, Inc. - Nasdaq
  4. News Immunovant, Inc.
  5. Sector Update: Health Care Stocks Decline Premarket Tuesday
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW